Having raised $82 million in its latest funding round, tech firm Cellares Corporation is looking to advance development of its cell therapy manufacturing platform, the Cell Shuttle.
We spoke with co-founder and CEO Fabian Gerlinghaus about the current limitations in CAR-T production and how the Cell Shuttles’ scalable, modular, and automated nature could be a gamechanger in the burgeoning space
Keep up with BioProcess Insider on our website.
Follow us on LinkedIn and Twitter:
